high mobility group box 3 pseudogene 21Genealiases: []
Q-omics provides the consensus-scored HMGB3P21 profile across patient tissues and cancer cell-line models. HMGB3P21 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HMGB3P21 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, HMGB3P21 RNA expression shows 11,945 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, and LSCC as cancer lineages where HMGB3P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P21 survival associations across molecular data types. HMGB3P21 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P21 RNA expression–survival associations across cancer types. High HMGB3P21 expression shows unfavorable associations in THCA, LGG and KIRC, but favorable associations in BLCA, LAML and OV. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .019). Together, the overview and detailed table identify BLCA as the clearest survival context for HMGB3P21 RNA expression.
This table summarizes HMGB3P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P21 shows lower tumor expression in KIRC, LUAD and KICH and higher tumor expression in BLCA, UCEC and PRAD. The BLCA box plot shows higher HMGB3P21 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .024).
This table shows molecular features associated with HMGB3P21 in patient tissues and cancer cell lines. In patient samples, HMGB3P21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
